

Table S1. Medians, IQR and ranges of anti-S/RBD antibody concentrations (AU/mL) at the three planned measurements post second dose of vaccine.

	I measurement median (IQR);(range)	II measurement median (IQR);(range)	III measurement median (IQR);(range)
days since II vaccination	16 (15-17); (12-37)	77 (76-78); (34-101)	154 (151-156); (122-243)
Anti-S antibodies for:			
all individuals	2.343 (1,516-3,531); (66-9,801)	563 (341-888); (36-2,914)	180 (107-303); (3-1,475)
males	1.697 (1,094-2,696); (124-6,937)	402 (288-709); (40-2,659)	146 (94-251); (1-155)
females	2.948 (1,706-3,746); (66-9,801)	621 (380-953); (36-2,914)	197 (114-322); (3-1,475)
p-values males vs females	<0.001	<0.001	0.001
age groups			
20-44	2.509 (1,645-3,754); (152-9,801)	636 (395-935); (36-2,659)	204 (121-346); (16-1,155)
45-55	2.173 (1,498-3,155); (282-9,248)	501 (308-854); (77-2,286)	158 (95-282); (30-901)
56-85	1.917 (1,096-3,101); (66-7,525)	436 (268-832); (40-2,914)	144 (80-244); (3-1,475)
p-values age groups	0.019	0.015	0.003
males aged:			
20-44	1.901 (1,300-2,801); (157-6,937)	460 (345-766); (48-2,659)	178 (109-290); (19-1,155)
45-55	1.596 (999-2,437); (282-5,058)	381 (282-570); (96-1,340)	126 (83-257); (31-473)
56-85	1.257 (726-2,978); (124-6,734)	302 (199-689); (40-1,776)	111 (77-166); (15-779)
p-values age groups	0.460	0.086	0.038
females aged:			
20-44	2.646 (1,814-3,952); (152-9,801)	668 (411-985); (36-2,541)	209 (134-363); (16-1,112)
45-55	2.258 (1,663-3,621); (289-9,248)	543 (341-913); (77-2,286)	169 (96-293); (30-901)
56-85	2.395 (1,313-3,458); (66-7,525)	601 (332-930); (40-2,914)	173 (93-305); (3-1,475)
p-values age groups	0.136	0.238	0.071